Upstream Bio, Inc. is a biotechnology company focused on developing innovative therapies for patients with severe allergic diseases and other immune-mediated conditions. The company utilizes its expertise in biologics and immunology to design and advance treatments that target underlying disease mechanisms. Upstream Bio aims to address unmet medical needs with the potential for transformative solutions, working through rigorous research and clinical trials to bring new options to the healthcare market. Their commitment to improving patient outcomes drives their research and development efforts, as they seek to enhance the quality of life for individuals suffering from these challenging conditions. Read More
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and Camp4 Therapeutics each made their public debut.
